Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 1
2019 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, Kogai T, Tomaru T, Usui I, Aso Y. Jojima T, et al. Among authors: wakamatsu s. Int J Mol Sci. 2019 Oct 22;20(20):5237. doi: 10.3390/ijms20205237. Int J Mol Sci. 2019. PMID: 31652578 Free PMC article.
Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
Jojima T, Sakurai S, Wakamatsu S, Iijima T, Saito M, Tomaru T, Kogai T, Usui I, Aso Y. Jojima T, et al. Among authors: wakamatsu s. Int J Cardiol. 2021 May 15;331:243-248. doi: 10.1016/j.ijcard.2021.01.063. Epub 2021 Feb 5. Int J Cardiol. 2021. PMID: 33556413 Clinical Trial.
The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Kato K, Suzuki K, Aoki C, Sagara M, Niitani T, Wakamatsu S, Yanagi K, Aso Y. Kato K, et al. Among authors: wakamatsu s. Expert Opin Pharmacother. 2017 Jun;18(8):743-751. doi: 10.1080/14656566.2017.1317748. Epub 2017 Apr 21. Expert Opin Pharmacother. 2017. PMID: 28426260 Clinical Trial.